[Clinical aspects, course and therapy of disseminated encephalomyelitis in chronic acquired toxoplasmosis].
D000293:Adolescent; D000328:Adult; D000981:Antiprotozoal Agents / Q000627:therapeutic use; D002908:Chronic Disease; D004359:Drug Therapy, Combination; D004679:Encephalomyelitis / Q000188:drug therapy / Q000209:etiology* / Q000503:physiopathology; D005132:Eye Manifestations; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D009461:Neurologic Manifestations; D011739:Pyrimethamine / Q000627:therapeutic use; D013418:Sulfamethazine / Q000627:therapeutic use; D014123:Toxoplasmosis / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology
D000981:Antiprotozoal Agents; D013418:Sulfamethazine; D011739:Pyrimethamine
Klinika, techenie i terapiia rasseiannogo éntsefalomielita pri khronicheskom priobretennom toksoplazmoze